Bayer - annualreport2007.bayer.com - Bayer Corporate News
General Information:
Latest News:
Nexavar® (sorafenib) Granted Priority Review for Differentiated Thyroid Cancer in the U.S. (for specialized target groups only) 27 Aug 2013 | 11:30 am
Currently no approved therapies specifically for differentiated thyroid cancer refractory to radioactive iodine
Bayer’s Stivarga® Approved for the Treatment of Patients with Gastrointestinal Stromal Tumors in Japan (for specialized target groups only) 20 Aug 2013 | 12:00 pm
U.S. FDA Advisory Committee Unanimously Recommends Approval of Bayer’s Riociguat in Two Forms of Pulmonary Hypertension (for specialized target groups... 7 Aug 2013 | 02:15 am
VEGF Trap-Eye (aflibercept solution for injection) Met Primary Endpoint in Two Phase 3 Trials for the Treatment of Diabetic Macular Edema (for special... 6 Aug 2013 | 11:30 am
Bayer: strong growth in Life Sciences 31 Jul 2013 | 10:30 am
HealthCare and CropScience post dynamic growth, MaterialScience weak / New pharmaceutical products well above expectations / Group sales rise 1.9 percent (Fx & portfolio adj. 4.6 percent) to EUR 10,36...
Bayer Receives Recommendation for Approval of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Visual Impairment due to Macular... 26 Jul 2013 | 06:00 pm
Bayer holds official 150th anniversary celebration 16 Jul 2013 | 08:40 pm
More than 1,000 guests in Cologne / German Chancellor Merkel: Bayer is an outstanding advertisement for Germany / North Rhine-Westphalian State Premier Kraft: We need the chemical industry for the sak...
Sorafenib (Nexavar®) Submitted to the EMA and FDA for the Treatment of Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thy... 1 Jul 2013 | 11:30 am
Currently no approved therapies specifically for differentiated thyroid cancer refractory to radioactive iodine / Regulatory submissions based on data from Phase III DECISION trial, in which sorafenib...
